---
annotation-target: v12p5986.pdf
---


>%%
>```annotation-json
>{"created":"2022-08-30T13:13:55.400Z","updated":"2022-08-30T13:13:55.400Z","document":{"title":"","link":[{"href":"urn:x-pdf:e416565746cfe94189eeb0bb2e48b4fe"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/v12p5986.pdf"}],"documentFingerprint":"e416565746cfe94189eeb0bb2e48b4fe"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/v12p5986.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/v12p5986.pdf","selector":[{"type":"TextPositionSelector","start":5260,"end":5715},{"type":"TextQuoteSelector","exact":"The value of positron emission tomography/computed  tomography  (PET/CT)  with  18F-labelled  fluorodeoxyglucose  (18F-FDG)  has  been  widely investigated in varying clinical conditions and is  recognized  as  a  useful  tool  in  the  management  of  patients with MM [6-11]. However, 18F-FDG PET/CT also has some limitations, such as lower sensitivity in detecting bone marrow involvement in MM patients, so alternative tracers have been investigated [","prefix":"on and response assessment [5]. ","suffix":"12-17].  C-X-C  motif  chemokine"}]}]}
>```
>%%
>*%%PREFIX%%on and response assessment [5].%%HIGHLIGHT%% ==The value of positron emission tomography/computed  tomography  (PET/CT)  with  18F-labelled  fluorodeoxyglucose  (18F-FDG)  has  been  widely investigated in varying clinical conditions and is  recognized  as  a  useful  tool  in  the  management  of  patients with MM [6-11]. However, 18F-FDG PET/CT also has some limitations, such as lower sensitivity in detecting bone marrow involvement in MM patients, so alternative tracers have been investigated [== %%POSTFIX%%12-17].  C-X-C  motif  chemokine*
>%%LINK%%[[#^qwlmmyur0ij|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^qwlmmyur0ij


>%%
>```annotation-json
>{"created":"2022-08-30T13:16:24.057Z","updated":"2022-08-30T13:16:24.057Z","document":{"title":"","link":[{"href":"urn:x-pdf:e416565746cfe94189eeb0bb2e48b4fe"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/v12p5986.pdf"}],"documentFingerprint":"e416565746cfe94189eeb0bb2e48b4fe"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/v12p5986.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/v12p5986.pdf","selector":[{"type":"TextPositionSelector","start":5724,"end":5763},{"type":"TextQuoteSelector","exact":"C-X-C  motif  chemokine  receptor  4  (","prefix":"ave been investigated [12-17].  ","suffix":"CXCR4)  is  a  rising ligand in "}]}]}
>```
>%%
>*%%PREFIX%%ave been investigated [12-17].%%HIGHLIGHT%% ==C-X-C  motif  chemokine  receptor  4  (== %%POSTFIX%%CXCR4)  is  a  rising ligand in*
>%%LINK%%[[#^ay9pkr7o8e|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ay9pkr7o8e


>%%
>```annotation-json
>{"created":"2022-08-30T13:16:37.496Z","updated":"2022-08-30T13:16:37.496Z","document":{"title":"","link":[{"href":"urn:x-pdf:e416565746cfe94189eeb0bb2e48b4fe"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/v12p5986.pdf"}],"documentFingerprint":"e416565746cfe94189eeb0bb2e48b4fe"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/v12p5986.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/v12p5986.pdf","selector":[{"type":"TextPositionSelector","start":6187,"end":6327},{"type":"TextQuoteSelector","exact":"the interplay between receptor and its ligand stromal derived factor 1 (SDF-1α/CXCL12)  serves  as  a stimulus of plasma cell proliferation ","prefix":" prognostic factor [20]. In MM, ","suffix":"[27]. 68Ga-Pentixafor, a synthet"}]}]}
>```
>%%
>*%%PREFIX%%prognostic factor [20]. In MM,%%HIGHLIGHT%% ==the interplay between receptor and its ligand stromal derived factor 1 (SDF-1α/CXCL12)  serves  as  a stimulus of plasma cell proliferation== %%POSTFIX%%[27]. 68Ga-Pentixafor, a synthet*
>%%LINK%%[[#^rnvdqi1tyvj|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^rnvdqi1tyvj


>%%
>```annotation-json
>{"created":"2022-08-30T13:17:18.551Z","updated":"2022-08-30T13:17:18.551Z","document":{"title":"","link":[{"href":"urn:x-pdf:e416565746cfe94189eeb0bb2e48b4fe"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/v12p5986.pdf"}],"documentFingerprint":"e416565746cfe94189eeb0bb2e48b4fe"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/v12p5986.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/v12p5986.pdf","selector":[{"type":"TextPositionSelector","start":6395,"end":6530},{"type":"TextQuoteSelector","exact":"ool for in vivo positron emission tomography (PET) imaging of many solid and hematologic  malignancies  [25,  28-32].  Noteworthy,  a  ","prefix":"igand of CXCR4, is a promising t","suffix":"wide heterogeneity not only of t"}]}]}
>```
>%%
>*%%PREFIX%%igand of CXCR4, is a promising t%%HIGHLIGHT%% ==ool for in vivo positron emission tomography (PET) imaging of many solid and hematologic  malignancies  [25,  28-32].  Noteworthy,  a== %%POSTFIX%%wide heterogeneity not only of t*
>%%LINK%%[[#^sd6x5movird|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^sd6x5movird
